NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to treat major neuropsychiatric ...

The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against ...

NHS England chair Penny Dash shared her views on European healthcare during a fireside discussion at HLTH Europe in Amsterdam ...

Bavarian Nordic has sold a PRV for $160m, a day after the FDA announced a new scheme utilising the fast-track tickets.

Tisento Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for zagociguat.